GlassScriptPhysician profile
Karen E Harris
NPI 1013981406
$1,245.70
in general payments reported to CMS, 2019-2025
26 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.79 · 2021: $172 · 2022: $279 · 2023: $303 · 2024: $152 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.51 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.41 | 2021-2025 | |
| Organon LLC | $103.13 | 2021-2024 | |
| Dysis Medical, INC. | $86.79 | 2019 | |
| Hologic Sales and Service, LLC | $83.10 | 2021-2024 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Astellas Pharma US INC | $72.91 | 2023-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $72.17 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $61.83 | 2022-2025 | |
| Myovant Sciences INC. | $60.27 | 2022 | |
| Sumitomo Pharma America, INC. | $53.06 | 2023-2025 | Myfembree, Gemtesa |
| Lsi Solutions INC | $47.42 | 2023 | Fornisee |
| Revvity, INC. | $46.94 | 2023 | |
| Shield Therapeutics INC | $41.17 | 2022-2024 | |
| Teleflex LLC | $35.38 | 2025 | Quikclot |
| Sage Therapeutics, LLC | $33.10 | 2022-2025 | Zurzuvae |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $29.60 | 2025 | Dexcom G6 Transmitter |
| Ethicon US, LLC | $24.18 | 2023 | Harmonic, Enseal, Surgicel Nu-Knit |
| Exeltis, USA INC. | $15.50 | 2025 | Slynd |
| Supernus Pharmaceuticals, INC. | $14.57 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $14.37 | 2023 | Gardasil 9 |
| Gynesonics, INC. | $13.75 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exact Sciences Corporation | $13.40 | 2023 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $12.59 | 2022 | |
| Medicem INC. | $11.33 | 2021 | |
| Channel Medsystems, INC. | $10.22 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.